We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
26
Insulet
PODD
$11.5B
$84.2M 1.19%
386,335
-11,854
-3% -$2.69M
OPCH icon
27
Option Care Health
OPCH
$3.42B
$80.2M 1.13%
2,887,259
-345,528
-11% -$9.83M
TNDM icon
28
Tandem Diabetes Care
TNDM
$1.2B
$77.9M 1.1%
1,315,873
+199,365
+18% +$16.4M
INSP icon
29
Inspire Medical Systems
INSP
$1.49B
$74.4M 1.05%
407,057
+9,551
+2% +$1.9M
MYOV
30
DELISTED
Myovant Sciences Ltd.
MYOV
$73.6M 1.04%
5,919,639
+60,600
+1% +$669K
INSM icon
31
Insmed
INSM
$23.7B
$71.4M 1.01%
3,621,562
+69,786
+2% +$1.46M
SWAV
32
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$70.9M 1%
370,699
-27,878
-7% -$4.92M
MOH icon
33
Molina Healthcare
MOH
$11.9B
$69.4M 0.98%
248,313
-54,484
-18% -$16.5M
DXCM icon
34
DexCom
DXCM
$29.6B
$69.2M 0.98%
928,508
-11,092
-1% -$1.01M
HUM icon
35
Humana
HUM
$47.8B
$68M 0.96%
145,309
-2,133
-1% -$949K
RLAY icon
36
Relay Therapeutics
RLAY
$4.23B
$67.5M 0.95%
4,032,262
+113,300
+3% +$2.43M
RVMD icon
37
Revolution Medicines
RVMD
$39.3B
$65.9M 0.93%
3,383,262
+72,600
+2% +$1.41M
EVH icon
38
Evolent Health
EVH
$646M
$62M 0.88%
2,018,521
-593,742
-23% -$17.3M
AMED
39
DELISTED
Amedisys
AMED
$61.5M 0.87%
585,154
+9,023
+2% +$1.15M
MDT icon
40
Medtronic
MDT
$107B
$57.9M 0.82%
645,506
-10,524
-2% -$1.07M
CRSP icon
41
CRISPR Therapeutics
CRSP
$4.66B
$56M 0.79%
922,005
-4,900
-0.5% -$288K
EXEL icon
42
Exelixis
EXEL
$14.2B
$55.8M 0.79%
2,678,500
-40,500
-1% -$835K
APLS
43
DELISTED
Apellis Pharmaceuticals
APLS
$54.6M 0.77%
1,206,422
+107,710
+10% +$4.91M
CDNA icon
44
CareDx
CDNA
$1.99B
$54.5M 0.77%
2,537,524
+226,348
+10% +$6.28M
CI icon
45
Cigna
CI
$75.2B
$51M 0.72%
193,657
-65,489
-25% -$16.9M
CRL icon
46
Charles River Laboratories
CRL
$10.5B
$49.4M 0.7%
231,069
+104,663
+83% +$25.6M
HCA icon
47
HCA Healthcare
HCA
$81.9B
$49.2M 0.7%
292,771
-7,426
-2% -$1.6M
OMCL icon
48
Omnicell
OMCL
$2.07B
$48.4M 0.68%
425,823
+63,491
+18% +$7.29M
CNC icon
49
Centene
CNC
$32.8B
$46.2M 0.65%
545,903
-114,732
-17% -$9.53M
BIO icon
50
Bio-Rad Laboratories Class A
BIO
$8.15B
$45.1M 0.64%
91,161
+19,152
+27% +$9.97M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.